C4X’s interims revealed a refinement of its hybrid business model, whereby it will stop offering access to its drug discovery technology on a fee-for-service basis, instead seeking to strike more strategic and collaborative agreements with pharma/biotech partners. The recent £1.67m acquisition of Adorial, with an innovative technology to help identify novel drug targets, could significantly enhance and accelerate C4X’s drug discovery capabilities. With £5m in cash as o
29 Mar 2016
A more refined approach
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A more refined approach
C4X Discovery Holdings Plc (C4XD:LON) | 9.1 0 0.0% | Mkt Cap: 23.0m
- Published:
29 Mar 2016 -
Author:
Linda Pomeroy -
Pages:
3
C4X’s interims revealed a refinement of its hybrid business model, whereby it will stop offering access to its drug discovery technology on a fee-for-service basis, instead seeking to strike more strategic and collaborative agreements with pharma/biotech partners. The recent £1.67m acquisition of Adorial, with an innovative technology to help identify novel drug targets, could significantly enhance and accelerate C4X’s drug discovery capabilities. With £5m in cash as o